ertugliflozin
Sign in to saveAlso known as MK-8835, PF-04971729, ertugliflozine
Ertugliflozin, sold under the brand name Steglatro, is a medication used for the treatment of type 2 diabetes.
Key facts
- Drug.image
- Ertugliflozin.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Steglatro
- Drug.DailyMedID
- Ertugliflozin
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.class
- Antidiabetic agent
- Drug.ATC_prefix
- A10
- Drug.ATC_suffix
- BK04
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.bioavailability
- ~100%
- Drug.protein_bound
- 93.6%
- Drug.metabolism
- UGT1A9, UGT2B7
- Drug.metabolites
- Glucuronides
- Drug.elimination_half life
- ~17 hours
via Wikipedia infobox
~4 min read
Encyclopedic overview
11 sectionsContents
- Medical uses
- Contraindications
- Adverse effects
- Overdose
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Society and culture
- Legal status
- References
Ertugliflozin, sold under the brand name Steglatro, is a medication used for the treatment of type 2 diabetes.
The most common side effects include fungal infections of the vagina and other infections of the female reproductive system.
Excerpted from Wikipedia’s “ertugliflozin” article, available under the CC BY-SA 4.0 licence.